• Find People
  • Campus Map
  • PiratePort
  • A-Z
    • About
    • Submit
    • Browse
    • Login
    View Item 
    •   ScholarShip Home
    • Health Sciences Campus
    • Brody School of Medicine
    • Microbiology and Immunology
    • View Item
    •   ScholarShip Home
    • Health Sciences Campus
    • Brody School of Medicine
    • Microbiology and Immunology
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of The ScholarShipCommunities & CollectionsDateAuthorsTitlesSubjectsTypeDate SubmittedThis CollectionDateAuthorsTitlesSubjectsTypeDate Submitted

    My Account

    Login

    Statistics

    View Google Analytics Statistics

    Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance

    Thumbnail
    View/ Open
    oncotarget-03-1068.PMC3717945.pdf (4.595Mb)

    Show full item record
    Author
    McCubrey, James A.; Steelman, Linda S.; Chappell, William H.; Abrams, Stephen L.; Franklin, Richard A.; Montalto, Giuseppe; Cervello, Melchiorre; Libra, Massimo; Candido, Saverio; Malaponte, Graziella; Mazzarino, Maria C.; Fagone, Paolo; Nicoletti, Ferdinando; Bäsecke, Jörg; Mijatovic, Sanja; Maksimovic-Ivanic, Danijela; Milella, Michele; Tafuri, Agostino; Chiarini, Francesca; Evangelisti, Camilla; Cocco, Lucio; Martelli, Alberto M.
    Abstract
    The Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades are often activated by genetic alterations in upstream signaling molecules such as receptor tyrosine kinases (RTK). Integral components of these pathways, Ras, B-Raf, PI3K, and PTEN are also activated/inactivated by mutations. These pathways have profound effects on proliferative, apoptotic and differentiation pathways. Dysregulation of these pathways can contribute to chemotherapeutic drug resistance, proliferation of cancer initiating cells (CICs) and premature aging. This review will evaluate more recently described potential uses of MEK, PI3K, Akt and mTOR inhibitors in the proliferation of malignant cells, suppression of CICs, cellular senescence and prevention of aging. Ras/Raf/MEK/ERK and Ras/PI3K/PTEN/Akt/mTOR pathways play key roles in the regulation of normal and malignant cell growth. Inhibitors targeting these pathways have many potential uses from suppression of cancer, proliferative diseases as well as aging.
    URI
    http://hdl.handle.net/10342/5687
    Subject
     Targeted Therapy,; Combination Therapy; Drug Resistance; Cancer Stem Cells; Aging; Senescence; Raf; Akt; PI3K; mTOR 
    Date
    2012-10
    Citation:
    APA:
    McCubrey, James A., & Steelman, Linda S., & Chappell, William H., & Abrams, Stephen L., & Franklin, Richard A., & Montalto, Giuseppe, & Cervello, Melchiorre, & Libra, Massimo, & Candido, Saverio, & Malaponte, Graziella, & Mazzarino, Maria C., & Fagone, Paolo, & Nicoletti, Ferdinando, & Bäsecke, Jörg, & Mijatovic, Sanja, & Maksimovic-Ivanic, Danijela, & Milella, Michele, & Tafuri, Agostino, & Chiarini, Francesca, & Evangelisti, Camilla, & Cocco, Lucio, & Martelli, Alberto M.. (October 2012). Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance. Oncotarget, 3(10), 1068- 1111. Retrieved from http://hdl.handle.net/10342/5687

    Display/Hide MLA, Chicago and APA citation formats.

    MLA:
    McCubrey, James A., and Steelman, Linda S., and Chappell, William H., and Abrams, Stephen L., and Franklin, Richard A., and Montalto, Giuseppe, and Cervello, Melchiorre, and Libra, Massimo, and Candido, Saverio, and Malaponte, Graziella, and Mazzarino, Maria C., and Fagone, Paolo, and Nicoletti, Ferdinando, and Bäsecke, Jörg, and Mijatovic, Sanja, and Maksimovic-Ivanic, Danijela, and Milella, Michele, and Tafuri, Agostino, and Chiarini, Francesca, and Evangelisti, Camilla, and Cocco, Lucio, and Martelli, Alberto M.. "Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance". Oncotarget. 3:10. (1068-1111), October 2012. September 28, 2023. http://hdl.handle.net/10342/5687.
    Chicago:
    McCubrey, James A. and Steelman, Linda S. and Chappell, William H. and Abrams, Stephen L. and Franklin, Richard A. and Montalto, Giuseppe and Cervello, Melchiorre and Libra, Massimo and Candido, Saverio and Malaponte, Graziella and Mazzarino, Maria C. and Fagone, Paolo and Nicoletti, Ferdinando and Bäsecke, Jörg and Mijatovic, Sanja and Maksimovic-Ivanic, Danijela and Milella, Michele and Tafuri, Agostino and Chiarini, Francesca and Evangelisti, Camilla and Cocco, Lucio and Martelli, Alberto M., "Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance," Oncotarget 3, no. 10 (October 2012), http://hdl.handle.net/10342/5687 (accessed September 28, 2023).
    AMA:
    McCubrey, James A., Steelman, Linda S., Chappell, William H., Abrams, Stephen L., Franklin, Richard A., Montalto, Giuseppe, Cervello, Melchiorre, Libra, Massimo, Candido, Saverio, Malaponte, Graziella, Mazzarino, Maria C., Fagone, Paolo, Nicoletti, Ferdinando, Bäsecke, Jörg, Mijatovic, Sanja, Maksimovic-Ivanic, Danijela, Milella, Michele, Tafuri, Agostino, Chiarini, Francesca, Evangelisti, Camilla, Cocco, Lucio, Martelli, Alberto M.. Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance. Oncotarget. October 2012; 3(10): 1068-1111. http://hdl.handle.net/10342/5687. Accessed September 28, 2023.
    Collections
    • Microbiology and Immunology

    xmlui.ArtifactBrowser.ItemViewer.elsevier_entitlement

    East Carolina University has created ScholarShip, a digital archive for the scholarly output of the ECU community.

    • About
    • Contact Us
    • Send Feedback